OBJECTIVE: The aim of this study was to investigate cognitive functions using auditory event-related brain potentials (ERP) in fibromyalgia syndrome (FMS). METHODS: The P300 component of ERP was studied in 36 female FMS patients and 22 control subjects. The short form 36 (SF-36) medical outcome study was used to determine quality of life. Number of tender points and disease duration were noted. Cognitive functions were evaluated with P300. RESULTS: The symptoms were discrepant in FMS (P<0.001). The scores of the eight SF-36 subgroups in FMS patients were significantly lower than in the control group (P<0.001). Fibromyalgia syndrome patients had prolonged latency and reduced amplitude of P300 (P<0.001). No correlation was found between the subgroups of SF-36, tender point count, disease duration, and P300. CONCLUSION: The results of our study reveal that FMS affects quality of life and dysfunction in cognitive abilities can be determined by brain event-related potentials.
OBJECTIVE: The aim of this study was to investigate cognitive functions using auditory event-related brain potentials (ERP) in fibromyalgia syndrome (FMS). METHODS: The P300 component of ERP was studied in 36 female FMS patients and 22 control subjects. The short form 36 (SF-36) medical outcome study was used to determine quality of life. Number of tender points and disease duration were noted. Cognitive functions were evaluated with P300. RESULTS: The symptoms were discrepant in FMS (P<0.001). The scores of the eight SF-36 subgroups in FMS patients were significantly lower than in the control group (P<0.001). Fibromyalgia syndromepatients had prolonged latency and reduced amplitude of P300 (P<0.001). No correlation was found between the subgroups of SF-36, tender point count, disease duration, and P300. CONCLUSION: The results of our study reveal that FMS affects quality of life and dysfunction in cognitive abilities can be determined by brain event-related potentials.
Authors: D Da Costa; P L Dobkin; M A Fitzcharles; P R Fortin; A Beaulieu; M Zummer; J L Senécal; J R Goulet; E Rich; D Choquette; A E Clarke Journal: J Rheumatol Date: 2000-02 Impact factor: 4.666
Authors: A W Al-Allaf; K L Dunbar; N S Hallum; B Nosratzadeh; K D Templeton; T Pullar Journal: Rheumatology (Oxford) Date: 2002-04 Impact factor: 7.580
Authors: C Sommer; W Häuser; K Gerhold; P Joraschky; F Petzke; T Tölle; N Uçeyler; A Winkelmann; K Thieme Journal: Schmerz Date: 2008-06 Impact factor: 1.107
Authors: Marina López-Solà; Jesus Pujol; Tor D Wager; Alba Garcia-Fontanals; Laura Blanco-Hinojo; Susana Garcia-Blanco; Violant Poca-Dias; Ben J Harrison; Oren Contreras-Rodríguez; Jordi Monfort; Ferran Garcia-Fructuoso; Joan Deus Journal: Arthritis Rheumatol Date: 2014-11 Impact factor: 10.995
Authors: Marina López-Solà; Choong-Wan Woo; Jesus Pujol; Joan Deus; Ben J Harrison; Jordi Monfort; Tor D Wager Journal: Pain Date: 2017-01 Impact factor: 7.926
Authors: Orla Moriarty; Nancy Ruane; David O'Gorman; Chris H Maharaj; Caroline Mitchell; Kiran M Sarma; David P Finn; Brian E McGuire Journal: Front Behav Neurosci Date: 2017-06-13 Impact factor: 3.558
Authors: Dina Dadabhoy; Leslie J Crofford; Michael Spaeth; I Jon Russell; Daniel J Clauw Journal: Arthritis Res Ther Date: 2008-08-08 Impact factor: 5.156